>>
news review Market
Corporate
First Patient in Chennai Treated with ABSORB Apollo Hospitals has successfully treated a coronary artery disease patient with the company’s revolutionary ABSORB drug eluting Bioresorbable Vascular Scaffold (BVS), thus becoming the first hospital in Chennai to use this innovative product. Abbott’s ABSORB is a groundbreaking device currently in clinical trials that is designed to restore blood flow by opening a clogged vessel and providing support while it heals. Once the vessel can remain open without the extra support, the bioresorbable scaffold is designed to be slowly metabolised and eventually dissolve and disappear from the body. Apollo Hospitals is the first in Chennai and one of the few hospitals in India to enroll a patient into the ABSORB EXTEND trial, a worldwide trial of up to 1,000 patients at 100 centers in Europe, Asia Pacific, Canada and Latin America. To date, approximately 200 patients have been implanted with the device, and data have been presented on patients at various time intervals,including 30 patients out to four years. Dr Pratap Reddy, Chairman, Apollo Hospitals said, “Introduction of this new device - Abbott ABSORB is part of our endeavor to bring in cutting edge technology to prevent and give the best possible outcome for coronary artery disease. I commend Abbott for developing this innovative product, Dr Mathew Samuel Kalarickal father of angioplasty for bringing this product first time to Chennai and Dr Sai Satish for bringing in a patient centric approach to cardiology.
ECG Telemetry Devices market to reach $1.1bn A report by Global Industry Analysts say that the global market for ECG telemetry devices is estimated to reach $1.1bn by 2015. The market will be driven by increasing cases of cardiovascular diseases and an ageing population. In addition, an increase in the number of modern chest-pain clinics and technology innovations will promote the increased adoption of telemetry ECG systems. The US represents the largest regional market for ECG telemetry devices in the world and, according to the report, the market will be driven by the increasing number of US citizens receiving home care. Asia-Pacific represents the fastest growing market for ECG telemetry devices. It is estimated to grow at a CAGR of more than 5% over the study period. Central display, control and recording stations is the largest product segment of ECG telemetry devices, while electrical leads will be the fastest growing, the report added.
Product
International
Glaucoma Detector for deteting glaucoma
Medtronic Provides Funding to Haiti
Scientists at the University of Arizona in the US have developed an instrument for detecting glaucoma, a disease caused by increased fluid pressure inside the eye. The project was funded by The National Science Foundation. The device is designed for self testing, and requires an individual has to rub a probe over the eyelid. This device, which can also measure drainage of intraocular fluid, uses a system of micro-force sensors and specially designed microchips, detects the stiffness of the eyelid and calculates the intraocular pressure.
Medtronic has announced funding of $750,000 to support healthcare infrastructure development in Haiti. The grant by Medtronic completes the $2.1m commitment the company made after the January 2010 earthquake in Haiti. About $500,000 will be provided to Partners in Health to facilitate the completion of construction of public hospital in Mirebalais. The hospital will improve clinical care and technical capacity, will accommodate a wider range of diagnostics and therapeutics, and serve as a major teaching hospital. The grant by Medtronic completes the $2.1m commitment the company made following the January 2010 earthquake in Haiti.
48
> www.ehealthonline.org > February 2011